Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itolizumab in ARDS caused by Infectious Pneumonia
NCT05978544Phase 1Not yet recruiting
- Start
- Dec 2023
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, open-label trial of itolizumab in acute respiratory distress syndrome (ARDS) (3 arms). Primary endpoint: Incidence of Treatment Emergent Adverse Events. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
itolizumab
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05978544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05978544.